Using Chimeric Antigen Receptor Modified T-Cell to Treat B-Cell Leukemias

Leukemias are cancers that happened in the blood of organisms, which affect the immune system’s T cells and B cells. Therefore, investigating studies to cure this disease are crucial. Several researchers demonstrated the use of modified receptors of T cells to fight leukemia. CTL019 (tisagenlecleucel) is a type of therapy that transplants the CD19 receptors into T cells to help them recognize the CD19+ B cells. They are used to detect and kill the cancerous B cell leukemia cells. The chimeric antigen receptor-modified T-cell (CAR-T) is a method that extracts the blood cells from the patients to cultivate the CD19 receptors. Finally, the blood would be injected back into the patients. Even though this method effectively kills CD19+ B-cells, it may have some side effects, such as the quick release of cytokines that can cause high systemic effects. With these side effects, scientists should investigate a better way to reduce the side effects in the future